
Corporate Governance3 Nov 2026, 02:25 pm
Akums Drugs IPO Proceeds Fully Utilized, CRISIL Reports
AI Summary
Akums Drugs and Pharmaceuticals Ltd has submitted the final report from CRISIL Ratings Limited, the monitoring agency, regarding the utilization of its Initial Public Offer (IPO) proceeds for the quarter ended September 30, 2026. The report confirms that 100% of the IPO proceeds have been fully utilized. Consequently, CRISIL Ratings will no longer be required to submit monitoring reports from the forthcoming quarter as per SEBI regulations. The IPO, which took place from July 30 to August 1, 2024, raised ₹6,800 million in gross proceeds, with net proceeds amounting to ₹6,421.80 million after accounting for revised offer expenses.
Key Highlights
- Final report on IPO proceeds utilization submitted by CRISIL.
- 100% of IPO proceeds have been fully utilized.
- Monitoring agency reporting to cease from next quarter.
- IPO raised ₹6,800 million in gross proceeds.
Price Impact
More from AKUMS